Estrogens and atherosclerosis

European Journal of Endocrinology

Volumn 150, Issue 2, 2004, Pages 113-117

  Arnal, J F ^a   Gourdy, P ^a   Elhage, R ^a   Garmy Susini, B ^a   Delmas, E ^a   Brouchet, L ^a   Castano, C ^a   Barreira, Y ^a   Couloumiers, J C ^a   Prats, H ^a   Prats, A C ^a   Bayard, F ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; ESTRADIOL; ESTROGEN DERIVATIVE; GAMMA INTERFERON; GESTAGEN; NITRIC OXIDE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNE RESPONSE; LIPID METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SHORT SURVEY; TH1 CELL; VASCULAR ENDOTHELIUM;

ANIMALS; ARTERIOSCLEROSIS; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ESTRADIOL; FEMALE; HUMANS; INFLAMMATION; MICE; MICE, KNOCKOUT; TH1 CELLS;

EID: 12144289007     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1500113     Document Type: Short Survey

References (40)

1. Hulley S, Grady D, Bush T, Furberg C, Herrington D & Riggs B. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 280 605-613.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321-333.
3. Arnal JF & Bayard F. Vasculoprotective effects of oestrogens. Clinical Experimental Pharmacology and Physiology 2001 28 1032-1034.
4. Hodgin JB & Maeda N. Minireview: estrogen and mouse models of atherosclerosis. Endocrinology 2002 143 4495-4501.
5. Bourassa P-A, Milos PM, Gaynor BJ, Breslow JL & Aiello RJ. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. PNAS 1996 93 10022-10027.
6. Elhage R, Arnal JF, Pierragi M-T, Duverger N, Fiévet C, Faye J-C et al. Estradiol-17β prevents fatty streak formation in apolipoprotein E-deficient mice. Arteriosclerosis Thrombosis and Vascular Biology 1997 17 2679-2684.
7. Marsh MM, Walker VR, Curtiss LK & Banka CL. Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. Journal of Lipid Research 1999 40 893-900.
8. Ross R. Atherosclerosis - an inflammatory disease. New England Journal of Medicine 1999 340 115-125.
9. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J & Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. PNAS 1995 92 8264-8268.
10. Dansky HM, Charlton SA, Harper MM & Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. PNAS 1997 94 4642-4646.
11. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR & Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. Journal of Clinical Investigation 1997 99 2752-2761.
12. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circulation Research 2001 89 E41-E45.
13. Lee TS, Yen HC, Pan CC & Chan LY. The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice. Arteriosclerosis Thrombosis and Vascular Biology 1999 19 734-742.
14. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF et al. Protective role of interleukin-10 in atherosclerosis. Circulation Research 1999 85 E17-E24.
15. Gourdy P, Mallat Z, Castano C, Garmy-Susini B, Mac Gregor JL, Tedgui A et al. The atheroprotective effect of 17 beta-estradiol is not altered in P-selectin- or ICAM-1-deficient hypercholesterolemic mice. Atherosclerosis 2003 166 41-48.
16. Virmani R, Kolodgie FD, Burke AP, Farb A & Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arteriosclerosis Thrombosis and Vascular Biology 2000 20 1262-1275.
17. Elhage R, Clamens S, Reardon-Alulis C, Getz GS, Fievet C, Maret A et al. Loss of atheroprotective effect of estradiol in immunodeficient mice. Endocrinology 2000 141 462-465.
18. Maret A, Coudert JD, Garidou L, Foucras G, Gourdy P, Krust A et al. Estradiol enhances primary antigen-specific CD4 T cell responses and Th1 development in vivo. Essential role of estrogen receptor alpha expression in hematopoietic cells. European Journal of Immunology 2003 33 512-521.
19. Alexander RW & Dzau VJ. Vascular biology: the past 50 years. Circulation 2000 102 IV112-116.
20. Libby P & Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001 103 1718-1720.
21. Thompson LP, Pinkas G & Weiner CP. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 2000 102 445-451.
22. Goetz RM, Thatte HS, Prabhakar P, Cho MR, Michel T & Golan DE. Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase. PNAS 1999 96 2788-2793.
23. Arnal JF, Clamens S, Pechet C, Negre-Salvayre A, Allera C, Girolami JP et al. Ethinylestradiol does not enhance the expression of nitric oxide synthase in bovine endothelial cells but increases the release of bioactive nitric oxide by inhibiting superoxide anion production. PNAS 1996 93 4108-4113.
24. Barbacanne MA, Rami J, Michel JB, Souchard JF, Philippe M, Besombes JP et al. Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: possible role of decreased endothelium-derived superoxide anion production. Cardiovascular Research 1999 41 672-681.
25. Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O & Maeda N. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. Journal of Clinical Investigation 2001 107 333-340.
26. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P & Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000 127 4277-4291.
27. Darblade B, Pendaries C, Krust A, Dupont S, Fouque MJ, Rami J et al. Estradiol alters nitric oxide production in the mouse aorta through the alpha-, but not beta-, estrogen receptor. Circulation Research 2002 90 413-419.
28. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS & Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. PNAS 1993 90 11162-11166.
29. Couse JF, Curtis SW, Washburn TF, Lindzey J, Golding TS, Lubahn DB et al. Analysis of transcription and estrogen insensitivity in the female mouse after targeted disruption of the estrogen receptor gene. Molecular Endocrinology 1995 9 1441-1454.
30. Pendaries C, Darblade B, Rochaix P, Krust A, Chambon P, Korach KS et al. The AF-1 activation-function of ERalpha may be dispensable to mediate the effect of estradiol on endothelial NO production in mice. PNAS 2002 99 2205-2210.
31. Elhage R, Bayard F, Richard V, Holvoet P, Duverger N, Fievet C et al. Prevention of fatty streak formation of 17beta-estradiol is not mediated by the production of nitric oxide in apolipoprotein E-deficient mice. Circulation 1997 96 3048-3052.
32. Krasinski K, Spyridopoulos I, Asahara T, van der Zee R, Isner JM & Losordo DW. Estradiol accelerates functional endothelial recovery after arterial injury. Circulation 1997 95 1768-1772.
33. Morales DE, McGowan KA, Grant DS, Maheshwari S, Bhartiya D, Cid MC et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995 91 755-763.
34. Bennett MR & O'Sullivan M. Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy. Pharmacology and Therapeutics 2001 91 149-166.
35. Farb A, Heller PF, Shroff S, Cheng L, Kolodgie FD, Carter AJ et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001 104 473-479.
36. Brouchet L, Krust A, Dupont S, Chambon P, Bayard F & Arnal JF. Estradiol accelerates reendothelialization in mouse carotid artery through estrogen receptor-alpha but not estrogen receptor-beta. Circulation 2001 103 423-428.
37. Guthridge M, Bertolini J, Cowling J, Runting A & Hearn MT. Localization of bFGF mRNA in cyclic rat ovary, diethylstilbesterol primed rat ovary, and cultured rat granulosa cells. Growth Factors 1992 7 15-25.
38. Prats H, Kaghad M, Prats AC, Klagsbrun M, Lelias JM, Liauzun P et al. High molecular mass forms of basic fibroblast growth factor are initiated by alternative CUG codons. PNAS 1989 86 1836-1840.
39. Florkiewicz RZ, Anchin J & Baird A. The inhibition of fibroblast growth factor-2 export by cardenolides implies a novel function for the catalytic subunit of Na+, K + -ATPase. Journal of Biological Chemistry 1998 273 544-551.
40. Kim-Schulze S, Lowe WL Jr & Schnaper HW. Estrogen stimulates delayed mitogen-activated protein kinase activity in human endothelial cells via an autocrine loop that involves basic fibroblast growth factor. Circulation 1998 98 413-421.